1. Home
  2. BVS vs DSGN Comparison

BVS vs DSGN Comparison

Compare BVS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bioventus Inc.

BVS

Bioventus Inc.

HOLD

Current Price

$14.38

Market Cap

783.2M

Sector

Health Care

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$14.99

Market Cap

853.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BVS
DSGN
Founded
2011
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
783.2M
853.8M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
BVS
DSGN
Price
$14.38
$14.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$14.00
$15.25
AVG Volume (30 Days)
810.2K
449.9K
Earning Date
05-06-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
163.46
N/A
EPS
0.52
N/A
Revenue
$568,087,000.00
N/A
Revenue This Year
$7.52
N/A
Revenue Next Year
$7.06
N/A
P/E Ratio
$27.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.26
$4.92
52 Week High
$15.89
$17.25

Technical Indicators

Market Signals
Indicator
BVS
DSGN
Relative Strength Index (RSI) 61.47 62.41
Support Level $7.29 $9.78
Resistance Level $15.89 $15.86
Average True Range (ATR) 0.78 0.61
MACD -0.06 0.18
Stochastic Oscillator 51.67 72.90

Price Performance

Historical Comparison
BVS
DSGN

About BVS Bioventus Inc.

Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: